Overview

A Study to Investigate the Safety and Effect of the Study Drug (FE 204205) in Patients With Cirrhotic Portal Hypertension

Status:
Terminated
Trial end date:
2017-09-27
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to investigate safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) after intravenous (IV) administration of FE 204205 in patients with cirrhotic portal hypertension.
Phase:
Phase 1
Details
Lead Sponsor:
Ferring Pharmaceuticals